Phenols
Medchemexpress LLC Guanoxabenz hydrochloride | 23256-40-8 | 283.54 | 25 MG
Guanoxabenz hydrochloride, also known as Hydroxyguanabenz hydrochloride, is an α2 adrenergic receptor agonist. It acts as a centrally active antihypertensive drug and is intended for research use only.
- Acts as an α2 adrenergic receptor agonist.
- Displays a Ki of 4000 nM for an α2A adrenoceptor, with 40 nM for its fully activated form.
- Recognized as a centrally active antihypertensive drug.
- High-affinity binding can be inhibited by N-hydroxyguanidine analogs and various metabolic inhibitors.
- Reduction to guanabenz, with higher affinity for alpha2A-adrenoceptors, is mediated by spleen cytosolic fraction.
- Induces high-affinity binding in rat brain membranes with NADH or NADPH cofactors.
- Causes a dose-related reduction in locomotor activity in vivo.
Medchemexpress LLC Tacrine hydrochloride | 1684-40-8 | 99.9% | 1 ML
Tacrine hydrochloride is a potent brain-penetrant inhibitor of both AChE and BChE. It also acts as an NMDAR inhibitor. This compound can be utilized in research related to Alzheimer's disease.
- Potent brain-penetrant inhibitor of AChE and BChE.
- NMDAR inhibitor.
- Used for Alzheimer's disease research.
- Appearance: Solid, white to light yellow.
- Shipping: Room temperature in continental US.
- Storage: 4°C, stored under nitrogen, away from moisture.
- In solvent storage: -80°C for 6 months; -20°C for 1 month (stored under nitrogen, away from moisture).
- Solubility in H2O: 33.33 mg/mL (141.99 mM; needs ultrasonic).
Medchemexpress LLC Guanoxabenz hydrochloride | 23256-40-8 | 283.54 | 1 ML
Guanoxabenz hydrochloride is an α2 adrenergic receptor agonist supplied as a 10 mM solution in 1 mL of DMSO, primarily used for research purposes.
- Functions as an α2 adrenergic receptor agonist.
- Suitable for in vitro and in vivo research.
- Provided as a 10 mM solution in DMSO.
- Purity greater than 99.7%.
- High-affinity binding inhibited by N-hydroxyguanidine analogs and metabolic inhibitors.
- Known as a centrally active antihypertensive drug.
- Causes dose-related reduction in locomotor activity.
Medchemexpress LLC MO-I-1100 | 1585217-40-8 | 99.8% | 379.81 | 25 MG
MO-I-1100 is an inhibitor of ASPH (Aspartyl-(Asparaginyl)-β-hydroxylase) enzymatic activity. It suppresses HCC cell migration, invasion, and anchorage independent growth. MO-I-1100 also shows antitumor effects by inhibiting the Notch signaling cascade in HCC.
- MO-I-1100 is an inhibitor of ASPH enzymatic activity.
- It suppresses HCC cell migration, invasion, and anchorage independent growth.
- MO-I-1100 shows antitumor effects by inhibiting the Notch signaling cascade in HCC.
- It inhibits the viability of FOCUS cells, which have high ASPH expression.
- MO-I-1100 reduces tumor growth in an intrahepatic orthotopic xenograft model of HCC.
- It reduces activated Notch 1 and downstream HES1 and HEY1 gene expression in vivo.
eMolecules Chem-Impex Triphenylmethylamine 1kg 386903847 31252 0 000 5824-40-8 MFCD00008047 259 352 C19H17N
Chem-Impex Triphenylmethylamine 1kg 386903847 31252 0 000 5824-40-8 MFCD00008047 259 352 C19H17N
eMolecules Combi-Blocks Tritylamine 1kg 357556858 OR-0537 98 000 5824-40-8 MFCD00008047 259 352 C19H17N
Combi-Blocks Tritylamine 1kg 357556858 OR-0537 98 000 5824-40-8 MFCD00008047 259 352 C19H17N
Medchemexpress LLC Cefmenoxime hydrochloride | 75738-58-8 | 99.3% | 5 G
Cefmenoxime hydrochloride is a new semisynthetic cephalosporin antibiotic. It demonstrates antibacterial activity against a broad range of gram-positive and gram-negative bacteria.
- Acts as a β-lactam antibiotic.
- Exhibits broad-spectrum activity against various bacteria.
- Inhibits at least 90% of tested Enterobacteriaceae strains (MIC90 0.06 to 8 μg/mL) in vitro.
- Effective against Streptococcus pneumoniae (MIC90 0.015 μg/mL), Streptococcus pyogenes (MIC90 ≤0.008 μg/mL), and S. aureus (MIC90 2 μg/mL) in vitro.
- Shows activity against Haemophilus influenzae, Neisseria gonorrhoeae, and Neisseria meningitidis (MIC90 ≤0.008 to 0.25 μg/mL) in vitro.
- Improves survival rate in mice infected with lung bacteria (40 mg/kg, daily for 7 days, 60% mortality reduction) in vivo.